Poster Presentation Title: No Association between Decreases in Serum Immunoglobulin Levels and Serious Infections with Long-Term Ublituximab Treatment in Patients with Relapsing Multiple Sclerosis ...
NEW YORK, Feb. 06, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data highlighting BRIUMVI ® (ublituximab-xiiy), to be presented at the Americas ...
Detailed price information for Tg Therapeutics (TGTX-Q) from The Globe and Mail including charting and trades.
(Barcelona, Spain, Thursday, 25 September 2025) New research presented today at the 41 st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2025) reveals ...
NEW YORK, Feb. 06, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data highlighting BRIUMVI ® (ublituximab-xiiy), to be presented at the Americas ...
The presentations will include findings related to infusion tolerability, safety, and the relationship between serum immunoglobulin levels and infections in patients with relapsing forms of multiple ...
NEW YORK, Feb. 18, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of presentations highlighting data from the ULTIMATE I & II Phase 3 trials and the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results